Suppr
超能文献

激素受体阳性、人表皮生长因子受体 2 阴性转移性乳腺癌的内分泌和靶向治疗-卡培他滨-氟维司群：ASCO 快速推荐更新。

Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.

机构信息

Dana Farber Cancer Institute, Boston, MA.

University of Pennsylvania, Philadelphia, PA.

出版信息

J Clin Oncol. 2024 Apr 20;42(12):1450-1453. doi: 10.1200/JCO.24.00248. Epub 2024 Mar 13.

DOI:10.1200/JCO.24.00248

PMID:38478799

Abstract

摘要

相似文献

Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.

J Clin Oncol. 2024 Apr 20;42(12):1450-1453. doi: 10.1200/JCO.24.00248. Epub 2024 Mar 13.

Testing for Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2023 Jun 20;41(18):3423-3425. doi: 10.1200/JCO.23.00638. Epub 2023 May 17.

Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2024 Jun 20;42(18):2233-2235. doi: 10.1200/JCO.24.00886. Epub 2024 May 20.

Systemic Therapy Update on Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2024 Nov;42(31):3751-3752. doi: 10.1200/JCO.23.02128. Epub 2023 Nov 6.

Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2022 Sep 10;40(26):3088-3090. doi: 10.1200/JCO.22.01533. Epub 2022 Aug 4.

Management of Stage III Non-Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2024 Sep 1;42(25):3058-3060. doi: 10.1200/JCO-24-01324. Epub 2024 Jul 23.

Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2023 Feb 20;41(6):1318-1320. doi: 10.1200/JCO.22.02807. Epub 2023 Jan 10.

Management of Metastatic Renal Clear Cell Cancer: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2023 Nov 20;41(33):5184-5186. doi: 10.1200/JCO.23.01977. Epub 2023 Oct 9.

Cancer Cachexia: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2023 Sep 1;41(25):4178-4179. doi: 10.1200/JCO.23.01280. Epub 2023 Jul 12.

Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2023 Sep 20;41(27):4430-4432. doi: 10.1200/JCO.23.01261. Epub 2023 Jul 20.

引用本文的文献

Capivasertib/Fulvestrant in patients with HR+, HER2-low or HER2-negative locally advanced or metastatic breast cancer.

Ther Adv Med Oncol. 2025 Jul 31;17:17588359251358947. doi: 10.1177/17588359251358947. eCollection 2025.

Capivasertib-induced polymorphous lichenoid exanthem: Report of a novel AKT kinase inhibitor-related drug eruption.

JAAD Case Rep. 2025 Jun 14;62:96-99. doi: 10.1016/j.jdcr.2025.05.022. eCollection 2025 Aug.

A real-world study of palbociclib plus endocrine therapy with or without a short course chemotherapy in the first-line treatment of HR-positive HER2-negative metastatic breast cancer.

Front Oncol. 2025 Jul 9;15:1512496. doi: 10.3389/fonc.2025.1512496. eCollection 2025.

Retrospective comparison between breast cancer tissue- and blood-based next-generation sequencing results in detection of PIK3CA, AKT1, and PTEN alterations.

Breast Cancer Res. 2025 Jul 1;27(1):122. doi: 10.1186/s13058-025-02055-0.

PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

Target Oncol. 2025 May;20(3):431-444. doi: 10.1007/s11523-025-01137-5. Epub 2025 May 6.

Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition).

Cancer Innov. 2025 Apr 9;4(3):e70008. doi: 10.1002/cai2.70008. eCollection 2025 Jun.

Identification of thyroid cancer biomarkers using WGCNA and machine learning.

Eur J Med Res. 2025 Apr 5;30(1):244. doi: 10.1186/s40001-025-02466-x.

An exposure-safety analysis to support the dosage of the novel AKT inhibitor capivasertib.

Cancer Chemother Pharmacol. 2025 Mar 28;95(1):48. doi: 10.1007/s00280-025-04775-8.

Capecitabine with aromatase inhibitors in the front-line therapy for metastatic breast cancer.

Breast Cancer. 2025 Mar 27. doi: 10.1007/s12282-025-01695-6.

Organoid models: applications and research advances in colorectal cancer.

Front Oncol. 2025 Feb 7;15:1432506. doi: 10.3389/fonc.2025.1432506. eCollection 2025.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

激素受体阳性、人表皮生长因子受体 2 阴性转移性乳腺癌的内分泌和靶向治疗-卡培他滨-氟维司群：ASCO 快速推荐更新。

Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译